Skip to main content

Table 5 Comparison of the PSA and ANN velocity in PCa and BPH patients

From: Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity

 

PSA velocity (PSAV)

ANN velocity (ANNV)

follow up group

PCa in %

(n = 49)

BPH in %

(n = 150)

PCa in %

(n = 49)

Difference to PSAV

BPH in %

(n = 150)

Difference to PSAV

increasing

71.4%

21.3%

44.9%

- 26.5%

10.7%

- 10.6%

stable*

18.4%

65.3%

34.7%

+ 16.3%

82.7%

+ 17.4%

decreasing

10.2%

13.3%

20.4%

+ 10.2%

6.7%

- 6.6%

  1. *by using the cutoff of 0.75 ng/mL/year for tPSA (range -0.75 to 0.75) and by using the cutoff of 4 per year for ANN output (range -4 to 4)